About the Journal

​​Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy.

Publication & Editorial Staff Contacts


Publication
Phil Daly
Phil.Daly@wolterskluwer.com

Production Editor
Asha Ladwa
Asha.Ladwa@​wolterskluwer.com


​Marketing
Danielle Beren
Danielle.Beren@wolterskluwer.com

Translation, Rights & Licensing
translationrights@wolterskluwer.com 
healthlicensing@wolterskluwer.com

Special Projects and Reprints (U.S./Canada)
Alan Moore
Alan.Moore@wolterskluwer.com

Reprints (non-U.S./Canada)
internationalreprints@wolterskluwer.com

Supplements
Phil Daly, Senior Publisher
Phone: +44 (0)203 197 6676
Phil.Daly@wolterskluwer.com

International Advertising Representative
Avia Potashnik
Advertising & Sponsorship Manager, Europe
Phone: +44 203 197 6722
E-mail: avia.potashnik@wolterskluwer.com

LWW Business Offices
Citi Building, 41st Floor
25 Canada Square
Canary Wharf
London E14 5LQ, UK
Phone: +44(0)20 3197 6500
www.lww.com

Editor-in-Chief
Mels Sluyser, PhD
The Netherlands Cancer Institute-H4
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands
Phone: +31 35 52 59 943
Fax: +31 20 51 22 029
m.sluyser@planet.nl